# Junta clínica — PT-pseudo_e91d5fe837cb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e91d5fe837cb",
  "pid": "PT-pseudo_e91d5fe837cb",
  "task": 1,
  "psa": 6.1,
  "age": 63,
  "months": 1,
  "pirads": "4",
  "psad": 0.12,
  "psav": 0.89,
  "psap": 5.3,
  "vol": 50.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.6372923,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia",
  "meds": "atorvastatin, simvastatin, rosuvastatin, tamsulosin",
  "notes": "PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 50 mL. DRE nodus. csPCa 0.64.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "77 kg",
    "height": "180 cm",
    "bmi": "23.8",
    "bp": "105/87 mmHg",
    "hr": "75 bpm",
    "smoking": "Ex-smoker (40 pack-yr, quit 2009)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring required due to previously confirmed malignancy and steadily climbing PSA levels."
    },
    {
      "s": "History",
      "t": "At age 63, this retired warehouse worker first entered clinical scrutiny for prostate irregularities toward the end of 2022. Medical background includes hypercholesterolaemia and chronic kidney disease, currently treated with atorvastatin, simvastatin, rosuvastatin, and tamsulosin. A 40 pack-year smoking history is noted, though cessation occurred back in 2009. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 1/35, and he explicitly denies pelvic discomfort or blood in the urine. Marital status is divorced, and he resides independently, relying on his grown son as his main point of contact. Daily habits include roughly 20 units of alcohol per week, while physical activity consists mainly of routine gardening instead of formal workouts. Commuting to the facility takes over an hour by rail. Recent outpatient visits covered routine thyroid evaluations, a surveillance colonoscopy under gastroenterology, and a vascular surgery assessment for varicose veins. He reports no unexplained weight reduction, skeletal pain, or systemic complaints, with his primary focus remaining strictly on prostate surveillance."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: moderately enlarged gland; right posterior peripheral zone contains a firm, discrete nodule; remainder presents as symmetrically smooth. General survey shows a well-nourished gentleman without signs of acute distress. Chest auscultation reveals clear breath sounds, and cardiovascular rhythm remains regular. Abdominal palpation yields a soft, non-tender cavity devoid of palpable masses or organ enlargement."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Divorced",
  "living": "Lives alone",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Gastroenterology — surveillance colonoscopy",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "20 units / week",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e91d5fe837cb
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 6.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.89 ng/mL/yr
  - Prior PSA: 5.3 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6372923 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 6.1 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 50 mL. DRE nodus. csPCa 0.64.

Vitals: weight 77 kg, height 180 cm, BMI 23.8, BP 105/87 mmHg, HR 75 bpm. Smoking: Ex-smoker (40 pack-yr, quit 2009).

Chief complaint: Ongoing monitoring required due to previously confirmed malignancy and steadily climbing PSA levels.

History: At age 63, this retired warehouse worker first entered clinical scrutiny for prostate irregularities toward the end of 2022. Medical background includes hypercholesterolaemia and chronic kidney disease, currently treated with atorvastatin, simvastatin, rosuvastatin, and tamsulosin. A 40 pack-year smoking history is noted, though cessation occurred back in 2009. Lower urinary tract complaints remain minimal, reflected by an IPSS score of 1/35, and he explicitly denies pelvic discomfort or blood in the urine. Marital status is divorced, and he resides independently, relying on his grown son as his main point of contact. Daily habits include roughly 20 units of alcohol per week, while physical activity consists mainly of routine gardening instead of formal workouts. Commuting to the facility takes over an hour by rail. Recent outpatient visits covered routine thyroid evaluations, a surveillance colonoscopy under gastroenterology, and a vascular surgery assessment for varicose veins. He reports no unexplained weight reduction, skeletal pain, or systemic complaints, with his primary focus remaining strictly on prostate surveillance.

Physical examination: DRE — texture: moderately enlarged gland; right posterior peripheral zone contains a firm, discrete nodule; remainder presents as symmetrically smooth. General survey shows a well-nourished gentleman without signs of acute distress. Chest auscultation reveals clear breath sounds, and cardiovascular rhythm remains regular. Abdominal palpation yields a soft, non-tender cavity devoid of palpable masses or organ enlargement.

Patient info: retired warehouse worker; Divorced; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 20 units / week; exercise Gardening, no structured exercise; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Gastroenterology — surveillance colonoscopy; Vascular surgery — varicose veins consult.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.07 epistemic (95% band 0.50-0.78); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.21: PI-RADS 4, PSA 13.2, PSAD 0.14, age 66, DRE Nodus -> BIOPSY (uncertain). He wrote: "There is no information on ISUP in the earlier cancer diagnosis and missing also size of earlier PIRADS 4 lesion"
  2. distance 1.23: PI-RADS 4, PSA 5.3, PSAD 0.1, age 56, DRE Nodus -> BIOPSY (clear). He wrote: "PIRADS 4 in a young man with a rapid increasing PSA"
  3. distance 1.33: PI-RADS 4, PSA 3.8, PSAD 0.126, age 70, DRE Nodus -> DEFER (borderline). He wrote: "stable MRi findings in 70yr with reasonably low PSA. prev biopsy finding without obvious indication for treatment. IF patient want to be very active in treatment, consid…"

PRECEDENT: BIOPSY (weighted vote 0.68 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the need for repeat biopsy when there is a lesion on MRI and the status of a prior biopsy. It states, "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." It also notes that "A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I find the bid for biopsy is not decisive because the guideline makes the decision dependent on the MRI status and the stability of the MRI, which is not fully resolved by the panel variables alone. EXPERT-COHORT, the criterion that the prior biopsy is positive does not determine the decision because the guideline makes the decision dependent on the documented grade of the prior biopsy and the surveillance history, which live in the previous notes.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA has normalized: if the PSA has normalised, a new PSA test can be performed after one year
laboratory_results - whether the PSA-D is low: a stable low PSA-D < 0.15 may exclude a repeat biopsy

THE FOLLOWING VALUES ARE ALREADY KNOWN and a line about any of them is wrong:
age - 63
PSA - 6.1 ng/mL
PI-RADS - 4
PSA density - 0.12 ng/mL²
prostate volume - 50.0 mL
DRE finding - Nodus
prior-biopsy status - Positive
csPCa probability - 0.6372923

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the surveillance history detailed in the previous notes, as the guideline suggests this is the deciding factor.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or status compared to an earlier study mandate a repeat biopsy?
  psa_trend (get_psa_trend) -> Has the PSA normalized, which might allow for a new PSA test after one year?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy, and is there an active surveillance protocol?
  laboratory_results (get_lab_results) -> Is the PSA density low enough (< 0.15) to potentially exclude a repeat biopsy?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior positive biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "discrete hypointense focus in the right posterior peripheral zone at mid-gland height, spanning roughly 14 x 10 x 12 mm."

psa_trend
Has the PSA normalized, which might allow for a new PSA test after one year?: No, the PSA has been rising from 2.9 (Oct 2022) to 6.1 (Jan 2025).

previous_notes
What is the grade of the prior biopsy, and is there an active surveillance protocol?: The grade of the prior biopsy is not recorded, and there is no mention of an active surveillance protocol.

laboratory_results
Is the PSA density low enough (< 0.15) to potentially exclude a repeat biopsy?: No, the PSA density is 0.12 ng/mL/mL, which is low enough.

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the documented prior biopsy grade and surveillance status.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 4 finding supports further investigation.
PSA trend shows a clear upward trajectory from 2.9 to 6.1 ng/mL.

AGAINST sampling this patient now
The guideline suggests that a stable low PSA-D < 0.15 may exclude a repeat biopsy.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.10 ng/mL over 4 points spanning 27 months; velocity +1.43 ng/mL per year; doubling time about 25 months.
PROJECTION at 6 months: 7.7 ng/mL, conformal 95% band 2.2-26.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.09 epistemic (95% band 0.40-0.74), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.64  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.57  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.68  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-STRUCTURED carried the most weight ('supports' tier). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions to the extent possible. The `previous_notes` explicitly state that the grade of the prior biopsy is not recorded and there is no mention of an active surveillance protocol, directly answering Q1 and Q2.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a weighted vote for BIOPSY based on the experts' scores, which is consistent with the findings that the critical information (prior grade/surveillance) was missing from the retrieved documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior positive biopsy? Answered by `previous_notes`: The grade is not recorded.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by `previous_notes`: There is no mention of an active surveillance protocol.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade and surveillance status carry the most weight because the EAU guideline explicitly states this information is the deciding factor. The rising PSA trend and low PSA density are secondary factors that do not override the missing critical data point.

MY SUGGESTION TO THE CHAIR
Given that the critical information required by the guideline is missing from the record, the decision cannot be definitively made based on the retrieved evidence alone.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

63y/o, PSA 6.1, PSAD 0.12, PI-RADS 4, prior biopsy grade not recorded. Rising PSA and unrecorded prior grade mandate sampling to determine management. Low PSAD argues against repeat biopsy, but the lack of prior grade necessitates tissue confirmation. Recommend biopsy for definitive staging.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
